Close Menu
Technology Mag

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Epic just won its Google lawsuit again, and Android may never be the same

    July 31, 2025

    DJI won’t sell you an Osmo 360 in the US — but these retailers will

    July 31, 2025

    Reddit wants to be a search engine now

    July 31, 2025
    Facebook X (Twitter) Instagram
    Subscribe
    Technology Mag
    Facebook X (Twitter) Instagram YouTube
    • Home
    • News
    • Business
    • Games
    • Gear
    • Reviews
    • Science
    • Security
    • Trending
    • Press Release
    Technology Mag
    Home » The First Crispr Medicine Is Now Approved in the US
    Science

    The First Crispr Medicine Is Now Approved in the US

    News RoomBy News RoomDecember 14, 20233 Mins Read
    Facebook Twitter Pinterest LinkedIn Reddit WhatsApp Email

    “This is a terrible disease,” says Samarth Kulkarni, president and CEO of Crispr Therapeutics. “Every day feels like a big burden. Patients have this constant specter of mortality hanging over them.”

    The culprit is abnormal hemoglobin, the protein that carries oxygen through the body. The problem arises from a mutation in the HBB gene. Everyone has two copies of the gene—one from each parent. Children born with sickle cell disease inherit a copy of the mutated gene from both parents.

    Casgevy uses the Nobel Prize–winning technology Crispr to modify patients’ cells so that they produce healthy hemoglobin instead. The Crispr system has two parts: a protein that cuts genetic material and a guide molecule that tells it where in the genome to make the cut.

    To do this, a patient’s stem cells are taken out of their bone marrow and edited in a laboratory. Scientists make a single cut in a different gene, called BCL11A, to turn on the production of a fetal form of hemoglobin that typically shuts off shortly after birth. This fetal version compensates for the abnormal adult hemoglobin. The edited cells are then infused back into the patient’s bloodstream.

    A total of 45 patients have received Casgevy in a clinical trial. Of the 31 patients followed for two years, 29 have been free of pain crises for at least a year after receiving a single dose of their own edited cells.

    Until now, the only cure for sickle cell has been a stem cell transplant from a closely related donor, but this option is available to only a small fraction of people. Transplants can also involve life-threatening risks and don’t always work.

    The first commercial patients to get Casgevy likely won’t be treated until early next year. It takes a few weeks to collect patients’ cells, edit them, and perform quality control checks before the cells are ready for infusion. “It takes a little bit of time to treat the patients,” Kulkarni says. “But we don’t want to waste any time—and patients don’t want to waste any time, because they’ve been waiting for this for a while.”

    Today, the FDA also approved a second type of gene treatment for sickle cell, called Lyfgenia. This therapy does not use Crispr to cut the genome but instead adds a therapeutic gene to cells so they can produce healthy hemoglobin. Made by Bluebird Bio of Somerville, Massachusetts, it also involves modifying patients’ cells outside the body. In a two-year trial, pain crises were eliminated in 28 out of 32 patients between six and 18 months after treatment with Lyfgenia.

    The FDA has put a black box warning on Lyfgenia—an indication of severe safety risks—since some patients who were treated with it have developed blood cancer. The agency says patients receiving it should be monitored for the rest of their lives.

    Alexis Thompson, chief of the division of hematology at Children’s Hospital of Philadelphia, says these new gene therapies will be transformative for patients. “I can now talk to parents about the possibility of their child perhaps being cured of sickle cell,” she says “A few years ago, I wouldn’t dare have that conversation with a family.”

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email
    Previous ArticleThe Best Travel Bags for Wherever You’re Headed
    Next Article Europe to End Robo-Firing in Major Gig Economy Overhaul

    Related Posts

    The Texas Floods Were a Preview of What’s to Come

    July 31, 2025

    Big Tech Asked for Looser Clean Water Act Permitting. Trump Wants to Give It to Them

    July 31, 2025

    What Your Nighttime Breathing Says About Your Health

    July 31, 2025

    How Do You Live a Happier Life? Notice What Was There All Along

    July 30, 2025

    EPA Employees Still in the Dark as Agency Dismantles Scientific Research Office

    July 30, 2025

    This Star System Contains 5 Potentially Habitable Planets

    July 30, 2025
    Our Picks

    DJI won’t sell you an Osmo 360 in the US — but these retailers will

    July 31, 2025

    Reddit wants to be a search engine now

    July 31, 2025

    Tim Cook says Apple is ‘open to’ AI acquisitions

    July 31, 2025

    Everything You Wanted to Know About China’s Auto Industry Takeover

    July 31, 2025
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss
    News

    Apple shipped its 3 billionth iPhone

    By News RoomJuly 31, 2025

    Apple has been the target of a fair amount of criticism over the past year,…

    Trump Ends Tariff Exemption for Small Packages

    July 31, 2025

    Apple says Trump’s tariffs are adding another $1 billion to its costs

    July 31, 2025

    US Senator Urges DHS to Probe Whether Agents Were Moved From Criminal Cases to Deportations

    July 31, 2025
    Facebook X (Twitter) Instagram Pinterest
    • Privacy Policy
    • Terms of use
    • Advertise
    • Contact
    © 2025 Technology Mag. All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.